Transcatheter Mitral Repair for Functional Mitral Regurgitation According to Left Ventricular Function: A Real-Life Propensity-Score Matched Study.
Mitraclip
functional mitral regurgitation
left ventricular ejection Fraction
transcatheter
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
09 Jun 2020
09 Jun 2020
Historique:
received:
28
04
2020
revised:
24
05
2020
accepted:
01
06
2020
entrez:
13
6
2020
pubmed:
13
6
2020
medline:
13
6
2020
Statut:
epublish
Résumé
Transcatheter mitral valve repair (TMVR) could improve survival in functional mitral regurgitation (FMR), but it is necessary to consider the influence of left ventricular ejection fraction (LVEF). Therefore, we compare the outcomes after TMVR with Mitraclip In an observational registry study, we compared the outcomes in patients with FMR who underwent TMVR with and without LVEF <30%. The primary endpoint was the combined one-year all-cause mortality and unplanned hospital readmissions due to HF. The secondary end-points were New York Heart Association (NYHA) functional class and mitral regurgitation (MR) severity. Propensity-score matching was used to create two groups with the same baseline characteristics, except for baseline LVEF. Among 535 FMR eligible patients, 144 patients with LVEF <30% (group 1) and 144 with LVEF >30% (group 2) had similar propensity scores and were included in the analyses. The primary study endpoint was significantlly higher in group 1 (33.3% vs. 9.4%, FMR patients with LVEF <30% treated with MitraClip
Sections du résumé
BACKGROUND
BACKGROUND
Transcatheter mitral valve repair (TMVR) could improve survival in functional mitral regurgitation (FMR), but it is necessary to consider the influence of left ventricular ejection fraction (LVEF). Therefore, we compare the outcomes after TMVR with Mitraclip
METHODS
METHODS
In an observational registry study, we compared the outcomes in patients with FMR who underwent TMVR with and without LVEF <30%. The primary endpoint was the combined one-year all-cause mortality and unplanned hospital readmissions due to HF. The secondary end-points were New York Heart Association (NYHA) functional class and mitral regurgitation (MR) severity. Propensity-score matching was used to create two groups with the same baseline characteristics, except for baseline LVEF.
RESULTS
RESULTS
Among 535 FMR eligible patients, 144 patients with LVEF <30% (group 1) and 144 with LVEF >30% (group 2) had similar propensity scores and were included in the analyses. The primary study endpoint was significantlly higher in group 1 (33.3% vs. 9.4%,
CONCLUSION
CONCLUSIONS
FMR patients with LVEF <30% treated with MitraClip
Identifiants
pubmed: 32526978
pii: jcm9061792
doi: 10.3390/jcm9061792
pmc: PMC7356666
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Ann Thorac Surg. 2004 Sep;78(3):794-9; discussion 794-9
pubmed: 15336993
Circulation. 2013 Apr 9;127(14):1485-92
pubmed: 23459614
N Engl J Med. 2018 Dec 13;379(24):2297-2306
pubmed: 30145927
N Engl J Med. 2018 Dec 13;379(24):2307-2318
pubmed: 30280640
Eur J Heart Fail. 2018 Mar;20(3):598-608
pubmed: 28834079
J Am Coll Cardiol. 2013 Sep 17;62(12):1052-1061
pubmed: 23747789
Eur J Intern Med. 2020 Feb 21;:
pubmed: 32094019
Circulation. 2011 Jun 14;123(23):2736-47
pubmed: 21670242
J Am Coll Cardiol. 2019 May 7;73(17):2123-2132
pubmed: 30894288
J Am Coll Cardiol. 2015 Mar 31;65(12):1231-1248
pubmed: 25814231
J Am Coll Cardiol. 2007 Jun 5;49(22):2191-201
pubmed: 17543639
JAMA Cardiol. 2017 Oct 1;2(10):1130-1139
pubmed: 28877291
J Am Coll Cardiol. 2014 Sep 2;64(9):875-84
pubmed: 25169171
Rev Esp Cardiol (Engl Ed). 2020 Jul;73(7):530-535
pubmed: 31405796
Heart. 2011 Oct;97(20):1675-80
pubmed: 21807656
Eur Heart J. 2017 Sep 21;38(36):2739-2791
pubmed: 28886619
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
Cardiol Ther. 2020 Jun;9(1):5-17
pubmed: 31820395
Can J Cardiol. 2016 Feb;32(2):259-65
pubmed: 26315351
Multivariate Behav Res. 2011 May;46(3):399-424
pubmed: 21818162
N Engl J Med. 2011 Apr 14;364(15):1395-406
pubmed: 21463154
JAMA Cardiol. 2018 Dec 1;3(12):1151-1159
pubmed: 30476950
J Am Soc Echocardiogr. 2017 Apr;30(4):303-371
pubmed: 28314623
Rev Esp Cardiol (Engl Ed). 2017 Sep;70(9):785-787
pubmed: 28126390
J Am Coll Cardiol. 2014 Dec 30;64(25):2792-801
pubmed: 25541133
Lancet. 2006 Sep 16;368(9540):1005-11
pubmed: 16980116
Rev Esp Cardiol (Engl Ed). 2019 Dec;72(12):994-997
pubmed: 31492599
Int J Cardiol. 2019 Sep 1;290:70-76
pubmed: 31109777
Heart. 2018 Feb;104(4):306-312
pubmed: 28663365
Rev Esp Cardiol (Engl Ed). 2019 Nov 12;:
pubmed: 31732437
J Am Coll Cardiol. 2017 Jul 11;70(2):252-289
pubmed: 28315732